Thermo Fisher posts Q2 2026 revenue up 10% y/y
Thermo Fisher reported Q2 2026 revenue of $11.99B, up 10% y/y (5% organic), and reiterated a 7% organic growth goal by 2028. CEO Marc Casper said AI-driven faster drug validation should lift pharma R&D and demand for lab tools and services.
Thermo Fisher Scientific Inc. 99B, up 10% y/y, including 5% organic growth. Management reiterated a 7% organic growth goal by 2028. CEO Marc Casper said AI-driven faster drug validation should support pharma R&D and demand for lab tools and services.